CN117883538A - Traditional Chinese medicine composition for treating acute gouty arthritis, preparation method and application - Google Patents
Traditional Chinese medicine composition for treating acute gouty arthritis, preparation method and application Download PDFInfo
- Publication number
- CN117883538A CN117883538A CN202311799303.XA CN202311799303A CN117883538A CN 117883538 A CN117883538 A CN 117883538A CN 202311799303 A CN202311799303 A CN 202311799303A CN 117883538 A CN117883538 A CN 117883538A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- gouty arthritis
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 79
- 201000005569 Gout Diseases 0.000 title claims abstract description 54
- 206010018634 Gouty Arthritis Diseases 0.000 title claims abstract description 45
- 230000001154 acute effect Effects 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 241000218176 Corydalis Species 0.000 claims abstract description 13
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 9
- 241000972673 Phellodendron amurense Species 0.000 claims abstract description 8
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 8
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 7
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 6
- 240000009022 Smilax rotundifolia Species 0.000 claims abstract description 6
- 235000003205 Smilax rotundifolia Nutrition 0.000 claims abstract description 6
- 240000006023 Trichosanthes kirilowii Species 0.000 claims abstract description 6
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 claims abstract description 6
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 5
- 241000132012 Atractylodes Species 0.000 claims abstract description 4
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 4
- 235000013976 turmeric Nutrition 0.000 claims abstract description 4
- 244000299790 Rheum rhabarbarum Species 0.000 claims abstract 2
- 238000002156 mixing Methods 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 244000269722 Thea sinensis Species 0.000 claims description 9
- 235000009569 green tea Nutrition 0.000 claims description 9
- 239000008517 radix Trichosanthis Substances 0.000 claims description 9
- 238000000227 grinding Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 7
- 239000011505 plaster Substances 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000003973 paint Substances 0.000 claims description 3
- 238000005496 tempering Methods 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 abstract description 27
- 208000024891 symptom Diseases 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 7
- 230000001976 improved effect Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 description 21
- 206010042674 Swelling Diseases 0.000 description 16
- 230000008961 swelling Effects 0.000 description 16
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 9
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 7
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 7
- 229940116269 uric acid Drugs 0.000 description 7
- 241000219061 Rheum Species 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000001503 joint Anatomy 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- 210000003857 wrist joint Anatomy 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000008407 joint function Effects 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000011837 pasties Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 235000014375 Curcuma Nutrition 0.000 description 2
- 240000009138 Curcuma zedoaria Species 0.000 description 2
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 240000004980 Rheum officinale Species 0.000 description 2
- 235000008081 Rheum officinale Nutrition 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000010409 ironing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 235000019509 white turmeric Nutrition 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000033822 gland development Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000000878 metatarsophalangeal joint Anatomy 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical group [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating acute gouty arthritis, a preparation method and application thereof, wherein the traditional Chinese medicine composition comprises the following raw material components in parts by weight: 10-15 parts of honeysuckle stem, 10-15 parts of amur corktree bark, 10-15 parts of rhubarb, 10-15 parts of glabrous greenbrier rhizome, 10-15 parts of Mongolian snakegourd root, 10-15 parts of turmeric, 10-15 parts of dahurian angelica root, 10-15 parts of swordlike atractylodes rhizome and 10-15 parts of rhizoma corydalis. The traditional Chinese medicine raw materials in the traditional Chinese medicine composition are all common traditional Chinese medicine materials in the current market, and are low in price and convenient to obtain. The patch of the traditional Chinese medicine composition for treating the acute gouty arthritis can be prepared under simple conditions, and clinical application results show that the total treatment effective rate of the patch for treating the acute gouty arthritis is 97.50%, the pain symptoms of the treatment part of a patient are obviously improved, and the CRP level is obviously reduced compared with that before treatment.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating acute gouty arthritis, a preparation method and application thereof.
Background
Acute gouty arthritis is an inflammatory joint disease caused by the deposition of monosodium urate in joint capsules, bursa, cartilage, bone and other tissues, is directly related to hyperuricemia caused by purine metabolic disorder and uric acid excretion reduction, and is clinically frequently manifested as acute, rapid and asymmetric red, swelling, fever and pain of joints, with 60-70% of patients first originating in the first metatarsophalangeal joint. In recent years, the incidence of gout rises year by year and has a tendency of younger, and the incidence of gout in China is incompletely counted to be 1% -3%.
The drugs currently used for the acute onset of gout are mainly nonsteroidal anti-inflammatory drugs, colchicine and glucocorticoid. All three medicines play a role in resisting inflammation, and although the medicines take effect quickly, the medicines have obvious damages to liver and kidney functions and digestive tracts of human bodies, and some patients cannot tolerate the medicines even, especially for a plurality of patients with acute gouty arthritis complicated with digestive tract ulcers, digestive tract hemorrhage and chronic liver and kidney insufficiency, therefore, the development of the Chinese patent medicine for treating the acute gouty arthritis with safety, reliability and good curative effect is very necessary. The external treatment method of the traditional Chinese medicine is used for treating the acute gouty arthritis, so that the application of the medicine can be reduced or even abandoned, the problem of red swelling and hot pain of joints can be rapidly solved, and the intermittent treatment is carried out.
The existing Chinese patent medicine for treating gouty arthritis is generally complex in preparation process, for example, chinese patent publication No. CN116173129A discloses an external Chinese medicinal ointment for treating acute gouty arthritis and a preparation method thereof, and the preparation process of the ointment is complex and has higher requirements on equipment; chinese patent publication No. CN114712434a discloses an ironing agent for treating acute gout and acute gouty arthritis, and the preparation process of the ironing agent requires repeated decoction of the medicine to extract a concentrated solution, which makes the preparation difficult. In addition, some of the traditional Chinese medicines also relate to traditional Chinese medicines or rare medicinal materials with high toxicity, so that great difficulty exists in popularization and application.
Disclosure of Invention
The invention provides a traditional Chinese medicine composition for treating acute gouty arthritis, a preparation method and application thereof, and aims to solve the technical problems that the existing traditional Chinese medicine for treating gouty arthritis is complex in preparation process or difficult to popularize.
According to one aspect of the invention, a traditional Chinese medicine composition for treating acute gouty arthritis is provided, which comprises the following raw material components in parts by weight: 10-15 parts of honeysuckle stem, 10-15 parts of amur corktree bark, 10-15 parts of rhubarb, 10-15 parts of glabrous greenbrier rhizome, 10-15 parts of Mongolian snakegourd root, 10-15 parts of turmeric, 10-15 parts of dahurian angelica root, 10-15 parts of swordlike atractylodes rhizome and 10-15 parts of rhizoma corydalis.
Further, the material comprises the following raw material components in parts by weight: caulis Lonicerae, cortex Phellodendri, radix et rhizoma Rhei, rhizoma Smilacis Glabrae, radix Trichosanthis, rhizoma Wenyujin Concisa, radix Angelicae Dahuricae, rhizoma Atractylodis, and rhizoma corydalis.
Further, the traditional Chinese medicine composition is prepared into a traditional Chinese medicine external preparation through a preparation process.
Further, the external preparation of the traditional Chinese medicine comprises a patch, powder, a paint, a paste, a tincture or an aerosol.
According to another aspect of the present invention, there is also provided a method for preparing a patch of a Chinese medicinal composition for treating acute gouty arthritis, comprising the steps of:
s1, mixing and grinding the raw material components in parts by weight to obtain drug particles;
s2, mixing the obtained drug particles with a blending agent according to the mass ratio of 1: (0.5-0.7) to obtain a blend;
s3, coating the obtained blend on a carrier to obtain the patch.
Further, S1 comprises the steps of mixing, grinding, mixing and grinding the raw material components in parts by weight to 100-200 meshes to obtain the drug particles.
Further, the blending agent includes purified water or green tea solution.
Further, the coating thickness is 2 to 3mm.
Further, the carrier comprises gauze or plaster.
According to another aspect of the invention, the invention also provides application of the traditional Chinese medicine composition for treating acute gouty arthritis in preparing a medicine for treating acute gouty arthritis.
The invention has the following beneficial effects:
the traditional Chinese medicine raw materials in the traditional Chinese medicine composition for treating acute gouty arthritis are all common traditional Chinese medicine materials in the current market, and the traditional Chinese medicine composition is low in price and convenient to obtain.
The preparation method of the patch for treating the acute gouty arthritis provided by the invention has simple conditions, and can be completed only by a pulverizer (or other machines with crushing functions), and the preparation can be completed under simple conditions.
The invention obtains satisfactory effect through clinical application in treating acute gouty arthritis (damp-heat accumulation), and is applied to clinic in 2017 beginning to be used for clinical observation of 40 cases of acute gouty arthritis (damp-heat accumulation) patients from 1 month in 2020 to 12 months in 2021, and after 5 days of treatment, 39 cases of patients are treated effectively, and the total treatment effective rate is 97.50%; not only the symptoms of joint redness, swelling and pain are rapidly relieved, but also CRP level is obviously reduced compared with that before treatment.
Detailed Description
In order to make the objects, technical solutions and advantageous technical effects of the present invention clearer, the present invention will be further described in detail with reference to examples. It should be understood that the examples described in this specification are for the purpose of illustrating the invention only and are not intended to limit the invention.
For simplicity, only a few numerical ranges are explicitly disclosed herein. However, any lower limit may be combined with any upper limit to form a range not explicitly recited; and any lower limit may be combined with any other lower limit to form a range not explicitly recited, and any upper limit may be combined with any other upper limit to form a range not explicitly recited. Furthermore, each point or individual value between the endpoints of the range is included within the range, although not explicitly recited. Thus, each point or individual value may be combined as a lower or upper limit on itself with any other point or individual value or with other lower or upper limit to form a range that is not explicitly recited.
In the description herein, unless otherwise indicated, "above" and "below" are intended to include the present number, "one or more" means two or more, and "one or more" means two or more.
The embodiment of the first aspect of the invention provides a traditional Chinese medicine composition for treating acute gouty arthritis, which comprises the following raw material components in parts by weight: 10-15 parts of honeysuckle stem, 10-15 parts of amur corktree bark, 10-15 parts of rhubarb, 10-15 parts of glabrous greenbrier rhizome, 10-15 parts of Mongolian snakegourd root, 10-15 parts of turmeric, 10-15 parts of dahurian angelica root, 10-15 parts of swordlike atractylodes rhizome and 10-15 parts of rhizoma corydalis.
'reason ' says that: the theory of external treatment is that of internal treatment, and the externally-treated herbs are that of internal treatment, which is different from the former. The medicine is directly applied to the affected part, and the effective components are directly absorbed into the channels and collaterals through skin, so as to play roles of clearing heat and removing dampness, freeing the obstruction of collaterals, reducing swelling and relieving pain, and avoid adverse reactions caused by the stimulation of oral medicine to the stomach and intestine.
Caulis Lonicerae: sweet and cold. Enter lung and stomach meridians. Clear away heat and toxic materials, dispel wind and dredge collaterals. Can be used for treating epidemic febrile disease, dysentery with blood heat, rheumatic arthralgia, and joint red swelling and pain.
Cortex Phellodendri: clearing heat and drying dampness, purging fire and removing steam, and detoxicating and treating sore. Has various pharmacological effects of resisting pathogenic microorganism, resisting inflammation, resisting allergic reaction, lowering blood pressure, resisting ulcer, lowering blood sugar, and resisting gout.
Rhubarb: purgation and accumulation, clearing heat and purging fire, cooling blood and detoxicating. Has the pharmacological effects of regulating gastrointestinal function, resisting inflammation and pathogenic microorganism, protecting cardiovascular and cerebrovascular, resisting tumor, protecting liver, promoting gallbladder function, and resisting aging.
Rhizoma smilacis glabrae: detoxification, dehumidification, joint promotion, pathogenic microorganism resistance, inflammation resistance, immune system regulation, myocardial protection, thrombus antagonism and other pharmacological effects.
Radix trichosanthis: is dried root of Trichosanthes kirilowii Maxim or Trichosanthes kirilowii Maxim belonging to Cucurbitaceae. Has effects in reducing blood sugar, regulating nervous system balance, promoting endocrine gland development, relieving fatigue, promoting digestion, protecting liver, and enhancing immunity.
Rhizoma Wenyujin Concisa: the pungent and warm ingredients are combined to break blood and promote qi circulation, unblock collaterals and relieve pain, dispel wind and treat arthralgia. Has antibacterial and analgesic effects.
Radix angelicae: dispelling wind, relieving pain, detumescence and expelling pus. Has antipyretic, antiinflammatory, analgesic, spasmolytic, and pathogenic microorganism resisting effects.
Rhizoma atractylodis: dispelling wind and cold, eliminating dampness and strengthening spleen. Has antibacterial and disinfectant effects.
Rhizoma corydalis: belongs to a blood activating and pain relieving medicine, and has the effects of easing pain, improving microcirculation and the like.
In the examples of the present application, the synergistic relationship of the components is as follows:
(1) The honeysuckle stem, the rhubarb and the phellodendron are all monarch drugs, so as to clear away heat and toxic materials and to treat the root;
(2) Rhizoma smilacis glabrae, radix angelicae and rhizoma atractylodis are all ministerial drugs, so that the effects of removing dampness and detoxifying, promoting the circulation of the joints and improving symptoms can be achieved;
(3) Rhizoma Wenyujin Concisa and rhizoma corydalis are adjuvant drugs for promoting blood circulation, activating qi-flowing and relieving pain, and can directly relieve pain of patients.
(4) Radix Trichosanthis is used as a guiding drug for clearing heat and promoting fluid production, relieving swelling and expelling pus, and avoiding damp-heat injuring yin.
The medicines are mixed and ground, a proper amount of dark green tea is used for blending to prepare paste, the paste is directly applied to an affected part, and the effective components are absorbed into the affected part through skin, so that the effects of clearing heat and removing dampness, freeing the obstruction of collaterals and relieving swelling and pain are achieved, the purposes of resisting inflammation, relieving fever and pain, inducing diuresis and relieving swelling are achieved, and the irritation of oral medicines to gastrointestinal tracts is avoided. The recipe has good curative effect on cellulitis and acute mastitis with skin not broken by external application in recent three years.
In some embodiments, to enhance the therapeutic effect, it is further preferred to include the same weight parts of the raw material components as follows: caulis Lonicerae, cortex Phellodendri, radix et rhizoma Rhei, rhizoma Smilacis Glabrae, radix Trichosanthis, rhizoma Wenyujin Concisa, radix Angelicae Dahuricae, rhizoma Atractylodis, and rhizoma corydalis.
In some embodiments, the traditional Chinese medicine composition is prepared into a traditional Chinese medicine external preparation through a preparation process. The external preparation of the traditional Chinese medicine comprises, but is not limited to, patches, powder, paint, ointment, tincture or aerosol, and a patient can select according to the conditions.
The traditional Chinese medicine raw materials in the traditional Chinese medicine composition for treating gout and gouty arthritis provided by the embodiment of the invention are all common traditional Chinese medicine materials in the current market, and the traditional Chinese medicine composition is low in cost and convenient to obtain.
An embodiment of another aspect of the present application provides a method for preparing a patch of a Chinese medicinal composition for treating gout and gouty arthritis, including the steps of:
s1, mixing and grinding the raw material components in parts by weight to obtain drug particles;
s2, mixing the obtained drug particles with a blending agent according to the mass ratio of 1: (0.5-0.7) to obtain a blend;
s3, coating the obtained blend on a carrier to obtain the patch.
The preparation method of the patch for treating gout and gouty arthritis provided by the invention has simple conditions, can be completed only by a pulverizer (or other machines with crushing functions), and can be completed under simple conditions.
In the embodiment of the application, S1 comprises the steps of mixing, grinding, mixing and grinding the raw material components in parts by weight to 100-200 meshes to obtain the drug particles. The active ingredients of the drug particles of the above particle size are easily absorbed at the time of use.
In embodiments of the present application, the tempering agent comprises purified water or green tea solution. The blended product blended by the blending agent has certain humidity, and is beneficial to drug adhesion and permeation.
In embodiments of the present application, the tempering agent comprises purified water or green tea solution. Green tea is used for blending, and the bitter and cool nature of the green tea can clear the channels and collaterals, damp and heat, and restrict the nature of rhizoma atractylodis in warming and drying, so that the effect of green tea after blending is better.
In the examples of the present application, the coating thickness is 2 to 3mm. The coating thickness of the blend is lower than 2mm, so that the drug effect is affected to a certain extent; the coating thickness of the formulation is more than 3mm, which is inconvenient to use.
In embodiments of the present application, the carrier includes, but is not limited to: gauze or plaster.
According to another aspect of the invention, the invention also provides application of the traditional Chinese medicine composition for treating acute gouty arthritis in preparing a medicine for treating acute gouty arthritis.
The patch provided by the embodiment achieves a satisfactory effect on treating acute gouty arthritis (damp-heat accumulation) through clinical application, is used for treating 40 cases of acute gouty arthritis (damp-heat accumulation) patients, and after 5 days of treatment, 39 cases of patients are effectively treated, and the total treatment effective rate is 97.50%; and the pain symptoms of the patients treated by the detoxification pain relieving plaster are obviously improved, and the CRP level is obviously reduced compared with that of the patients before treatment.
Examples
The following examples more particularly describe the disclosure of the present application, which are intended as illustrative only, since numerous modifications and variations within the scope of the disclosure will be apparent to those skilled in the art. Unless otherwise indicated, all parts, percentages, and ratios reported in the examples below are by weight, and all reagents used in the examples are commercially available or were obtained synthetically according to conventional methods and can be used directly without further treatment, as well as the instruments used in the examples.
Example 1
The patch for treating acute gouty arthritis is prepared from 15g of honeysuckle stem, phellodendron bark, rhubarb, glabrous greenbrier rhizome, radix trichosanthis, rhizoma curcumae longae, angelica dahurica, rhizoma atractylodis and rhizoma corydalis according to the following weight ratio:
(1) Weighing 15g of honeysuckle stem, phellodendron bark, rhubarb, glabrous greenbrier rhizome, radix trichosanthis, curcuma longa, angelica dahurica, rhizoma atractylodis and rhizoma corydalis respectively, fully mixing, crushing into 100 meshes by using a wall breaking machine, and uniformly mixing to obtain mixed medicinal powder for standby;
(2) Adding purified water with the weight of 0.5 times of the mixed powder in the step (1), fully and uniformly mixing to be pasty, uniformly coating on a patch, and controlling the thickness to be 2-3 mm to obtain the patch.
Example 2
(1) Weighing 12g of honeysuckle stem, 15g of phellodendron bark, 12g of rheum officinale, 15g of rhizoma smilacis glabrae, 15g of radix trichosanthis, 15g of curcuma zedoary, 15g of radix angelicae, 15g of rhizoma atractylodis and 15g of rhizoma corydalis, fully mixing, crushing into 150-mesh powder by using a wall breaking machine, and uniformly mixing to obtain mixed medicinal powder for later use;
(2) Adding the mixed powder obtained in the step (1) into green tea with the weight of 0.7 times of the powder, fully and uniformly mixing to be pasty, uniformly coating on a patch, and controlling the thickness to be 2-3 mm to obtain the patch.
Example 3
(1) Weighing 15g of honeysuckle stem, 15g of phellodendron bark, 15g of rheum officinale, 10g of rhizoma smilacis glabrae, 10g of radix trichosanthis, 10g of curcuma zedoary, 10g of radix angelicae, 10g of rhizoma atractylodis and 10g of rhizoma corydalis, fully mixing, crushing into 200-mesh powder by using a wall breaking machine, and uniformly mixing to obtain mixed medicinal powder for standby;
(2) Adding purified water with the weight of 0.7 times of the mixed powder in the step (1), fully and uniformly mixing to be pasty, uniformly coating on a patch, and controlling the thickness to be 2-3 mm to prepare the patch.
The patches prepared in examples 1 to 3 were subjected to clinical studies as follows:
1. case inclusion and exclusion criteria
The patient accords with the diagnosis standard of acute gouty arthritis in the 'primary gout diagnosis and treatment guide'; the patient accords with the syndrome differentiation standard about damp-heat accumulation in the traditional Chinese medicine syndrome diagnosis curative effect standard issued by the medical administration in 1994.
Exclusion criteria: (1) those with non-acute onset; (2) allergic persons to the drugs used in the study; (3) combining severe primary disease patients; (4) skin-damaged person; (5) and combining the mental diseases.
Using a random number method, 40 patients are listed in an observation group, and 40 patients are listed in a control group; patients in the observation group were treated with the traditional Chinese medicine patch of this example, and patients in the control group were treated with diclofenac diethylamine emulsion agent as usual.
2. Therapeutic effect criterion
Referring to the "clinical guidelines for new traditional Chinese medicine", the therapeutic effect index is calculated by nimodipine scoring method [ therapeutic effect index= (pre-treatment score-post-treatment score)/pre-treatment score x 100% ], and comprehensive evaluation is performed on the therapeutic effect: a. clinical control: the symptoms completely disappear, the joint functions are normal, and the curative effect index is more than or equal to 95%; b. the effect is shown: the symptoms are basically disappeared, the joint function is basically improved, and the curative effect index is more than or equal to 70% and less than 95%; c. the method is effective: the symptoms are improved, the joint function is improved, and the curative effect index is more than or equal to 30% and less than 70%; d. invalidation: no improvement of symptoms, no change of joints and a curative effect index less than 30 percent. Total effective rate = (clinical control + efficacy) number of cases/total number of cases x 100%.
3. Treatment details.
All patients strictly manage diet (low in purine) and properly increase water intake; oral meloxicam tablet (manufacturer: yangzui pharmaceutical Co., ltd.; approval mark: national drug standard character H20010207), 1 tablet/time, 1 time/d.
The treatment group was treated with the patch prepared in example 1, and applied to the red, swelling, heat and pain sites of patients for 4 hours, 2 times/d. The control group was treated with diclofenac diethylamine emulsion (manufacturer: beijing Nohua pharmaceutical Co., ltd.; approval mark: national drug standard H20140361), and the pain area was externally applied with an appropriate amount of the drug 2 times/d.
Both groups of patients were treated for 5d.
4. Therapeutic effects
Of the 40 patients in the treatment group, 7 patients had clinical control of the disease condition, 9 patients had significant treatment effects, and 23 patients had effective treatment, with a treatment effective rate of 97.50%. Of 40 patients in the control group, 3 patients had clinical control of the disease condition, 7 patients had significant treatment effects, and 24 patients had effective treatment, with a treatment effective rate of 85.00%.
5. Typical cases
Case (1): wu Mou Man, 87 years old
Initial diagnosis: bilateral knee redness and swelling pain for 7 days, VAS pain scores: and 6 minutes. Blood uric acid level is 623umol/L, and acute gouty arthritis is diagnosed.
Examination of the sample: the right knee joint is significantly red (3 degrees). Bilateral knee joint tenderness is obvious and walking is difficult.
Treatment: the affected part of the wet compress patient was wrapped with the patch prepared in example 2, 1 time per day, and the single application time was 3 hours.
And (5) re-diagnosis: the gouty arthritis treatment is carried out for 5 days, the symptoms of red swelling and pain of the left foot are disappeared, the blood uric acid level is 409umol/L, and the examination is carried out: the knee joints at the two sides have no red swelling and tenderness and limited movement.
Case (2): liao Mou Man, 87 years old
Initial diagnosis: left ankle joint red swelling pain for more than 1 month, VAS pain scores were: 7 minutes. The blood uric acid level is 740umol/L, and the acute gouty arthritis is diagnosed.
Examination of the sample: the left ankle joint was significantly red and swollen (3 degrees). Joint tenderness is obvious and walking is difficult.
Treatment: the affected part of the wet compress patient was wrapped with the patch prepared in example 31 time a day.
And (5) re-diagnosis: gouty arthritis treatment was repeated for 5 days, red swelling and pain symptoms of left ankle had disappeared, blood uric acid level was 285umol/L, and examination of the examination was performed: the joints have no red swelling and tenderness, and the movement is not limited.
Case (3): kang Mou Male, 64 years old
Initial diagnosis: in the past, there is a history of gouty arthritis, and the right wrist joint is obviously red and swollen (2 degrees). VAS pain scores were: 4 minutes. The uric acid level in blood was 519umol/L.
Examination of the sample: the right wrist joint is red, swollen and painful and difficult to flex and stretch.
Treatment: the traditional Chinese medicine powder prepared in the step (1) of the embodiment 2 is prepared by purified water, and then the traditional Chinese medicine powder is wrapped by gauze and wet-applied to the affected part of a patient for 1 time per day.
And (5) re-diagnosis: the symptoms of red swelling and pain of the wrist joint are obviously improved after the treatment is carried out for 5 days, the symptoms of the pain of the wrist joint are basically disappeared after 7 days, the movement is free, and the blood uric acid level is 196umol/L.
While the present application has been described with reference to a preferred embodiment, various modifications may be made and equivalents may be substituted for elements thereof without departing from the scope of the present application, and in particular, the technical features mentioned in the various embodiments may be combined in any manner as long as there is no structural conflict. The present application is not limited to the specific embodiments disclosed herein, but encompasses all technical solutions falling within the scope of the claims.
Claims (10)
1. The traditional Chinese medicine composition for treating acute gouty arthritis is characterized by comprising the following raw material components in parts by weight: 10-15 parts of honeysuckle stem, 10-15 parts of amur corktree bark, 10-15 parts of rhubarb, 10-15 parts of glabrous greenbrier rhizome, 10-15 parts of Mongolian snakegourd root, 10-15 parts of turmeric, 10-15 parts of dahurian angelica root, 10-15 parts of swordlike atractylodes rhizome and 10-15 parts of rhizoma corydalis.
2. The traditional Chinese medicine composition for treating acute gouty arthritis according to claim 1, which is characterized by comprising the following raw material components in parts by weight: caulis Lonicerae, cortex Phellodendri, radix et rhizoma Rhei, rhizoma Smilacis Glabrae, radix Trichosanthis, rhizoma Wenyujin Concisa, radix Angelicae Dahuricae, rhizoma Atractylodis, and rhizoma corydalis.
3. The traditional Chinese medicine composition for treating acute gouty arthritis according to claim 1 or 2, wherein the traditional Chinese medicine composition is prepared into a traditional Chinese medicine external preparation through a preparation process.
4. The traditional Chinese medicine composition for treating acute gouty arthritis according to claim 1 or 2, wherein the external preparation form of the traditional Chinese medicine comprises a patch, powder, a paint, a paste, a tincture or an aerosol.
5. A method for preparing a patch of the traditional Chinese medicine composition for treating acute gouty arthritis according to claim 4, comprising the following steps:
s1, mixing and grinding the raw material components in parts by weight to obtain drug particles;
s2, mixing the obtained drug particles with a blending agent according to the mass ratio of 1: (0.5-0.7) to obtain a blend;
s3, coating the obtained blend on a carrier to obtain the patch.
6. The method according to claim 5, wherein S1 comprises mixing and grinding the raw material components in parts by weight to 100-200 mesh to obtain the drug particles.
7. The method of claim 5, wherein the tempering agent comprises purified water or green tea solution.
8. The method of claim 5, wherein the coating thickness is 2 to 3mm.
9. The method of claim 5, wherein the carrier comprises gauze or plaster.
10. The use of a Chinese medicinal composition for treating acute gouty arthritis according to any one of claims 1 to 4 in the preparation of a medicament for treating acute gouty arthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311799303.XA CN117883538A (en) | 2023-12-26 | 2023-12-26 | Traditional Chinese medicine composition for treating acute gouty arthritis, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311799303.XA CN117883538A (en) | 2023-12-26 | 2023-12-26 | Traditional Chinese medicine composition for treating acute gouty arthritis, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117883538A true CN117883538A (en) | 2024-04-16 |
Family
ID=90644959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311799303.XA Pending CN117883538A (en) | 2023-12-26 | 2023-12-26 | Traditional Chinese medicine composition for treating acute gouty arthritis, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117883538A (en) |
-
2023
- 2023-12-26 CN CN202311799303.XA patent/CN117883538A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102319350A (en) | External scald oil medicinal composition for treating burns and scalds | |
| CN115770279B (en) | Traditional Chinese medicine composition for treating chronic lower limb vein diseases, decoction and preparation thereof | |
| CN101143171B (en) | Traditional Chinese medicine and its preparation method and its application | |
| AU2020103082A4 (en) | Traditional chinese medicine composition, traditional chinese medicine compound preparation for treating gout and preparation method thereof | |
| CN112107609B (en) | Application of Jingu lotus preparation in preparing medicine for treating chalazion | |
| CN103735927B (en) | A kind of Chinese medicine composition for the treatment of acute stage of gout and preparation method thereof | |
| CN108498617A (en) | Rheumatalgia Chinese medicine composition and its preparation method and application, lavipeditum packet and preparation method thereof and pharmaceutical preparation | |
| CN101057922A (en) | Traditional Chinese medicine preparation for treating vitiligo | |
| CN117883538A (en) | Traditional Chinese medicine composition for treating acute gouty arthritis, preparation method and application | |
| CN1730048A (en) | Chinese medicinal composition for treating piles and anal fissure and process for preparing the same | |
| CN103908600A (en) | Externally-applied medicine for treating rheumatoid arthritis damp-heat blockage symptom as well as preparation method and administration method thereof | |
| CN100556425C (en) | A kind of Chinese medicine unguentum of analgetic, hemostatic repercussive and sore-arresting functions | |
| CN116570699B (en) | Traditional Chinese medicine composition for treating pulmonary nodules as well as preparation and application thereof | |
| CN116763834B (en) | Traditional Chinese medicine composition and preparation for treating arthralgia as well as preparation method and application of traditional Chinese medicine composition and preparation | |
| CN114028487B (en) | Pharmaceutical composition and preparation for treating acute soft tissue injury | |
| JP7362140B2 (en) | Chinese herbal medicine topical patch for treating gouty joint pain and its preparation method | |
| CN106668787A (en) | Traditional Chinese medicine honeyed pill for treating hepatonecrosis and liver cancer and preparation method of traditional Chinese medicine honeyed pill | |
| CN108066738B (en) | Ointment for treating gouty arthritis and preparation method thereof | |
| CN106860646B (en) | Traditional Chinese medicine composition for treating gastroduodenal ulcer and preparation method thereof | |
| CN101194940A (en) | Anti-inflammation medicament for treating toothache and preparation method thereof | |
| CN105477246A (en) | Traditional Chinese medicine composition for treating phlegmatic hygrosis type mammary gland hyperplasia and preparation method thereof | |
| CN104971209A (en) | Externally used agent for treating tinea pedis and preparation method thereof | |
| CN104623050B (en) | A kind of medicament for the treatment of corticosteroid femur head necrosis | |
| CN114712423A (en) | Traditional Chinese medicine formula for colitis and preparation method | |
| CN104666676A (en) | Traditional Chinese medicinal composition for treating psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |